Deal Watch: AbbVie Cancels Shire Buyout, Blaming U.S. Tax Policy Revisions

Actavis potentially bolsters its GI franchise by optioning rights to peptide ghrelin agonist relamorelin and also the opportunity to buy out Rhythm Health. Meanwhile, Celgene increases its stake in Sutro and Janssen joins the Ebola fight.